Hayashi T, Nishikawa T, Koga I, Uchida Y, Horiguchi J, Yamawaki S
Department of Psychiatry and Neurosciences, Hiroshima University School of Medicine, Minami-ku, Japan.
Psychopharmacology (Berl). 1997 Apr;130(4):382-6. doi: 10.1007/s002130050254.
Animal studies have suggested the involvement of the adrenergic system in drinking behavior. The present study investigated the involvement of the alpha2-adrenergic system in the polydipsia of patients with chronic schizophrenia by use of an alpha2 agonist and an antagonist. Four patients with schizophrenic disorders accompanied by intermittent hyponatremia and polydipsia were the subjects of, and completed, this study. Drinking behavior was assessed by calculating the percent of maximum weight gain [PMWG: (maximum diurnal weight - standard weight) x 100/standard weight]. Standard weight was defined as body weight after 8 h of water restriction. Clonidine (75, 150, and 225 mg/day) increased the PMWG in a dose-dependent manner in the four subjects. In contrast, in three of the subjects, mianserin (30, 60, and 90 mg/day) decreased PMWG, and the severe polydipsia disappeared almost completely. These findings indicate clearly that the alpha2-adrenergic system is involved in the drinking behavior of schizophrenic patients. Mianserin appears to be clinically useful in treating such patients with polydipsia.
动物研究表明，肾上腺素能系统参与饮水行为。本研究通过使用α2激动剂和拮抗剂，调查了α2肾上腺素能系统在慢性精神分裂症患者烦渴症中的作用。四名伴有间歇性低钠血症和烦渴症的精神分裂症患者参与并完成了本研究。通过计算最大体重增加百分比[PMWG：（日间最大体重 - 标准体重）×100/标准体重]来评估饮水行为。标准体重定义为禁水8小时后的体重。可乐定（75、150和225毫克/天）在四名受试者中以剂量依赖方式增加了PMWG。相比之下，在三名受试者中，米安色林（30、60和90毫克/天）降低了PMWG，严重的烦渴症几乎完全消失。这些发现清楚地表明，α2肾上腺素能系统参与了精神分裂症患者的饮水行为。米安色林在临床上似乎对治疗此类烦渴症患者有用。
